American Society of Hematology

SHERPA: Blue

People

  1. Giralt
    Giralt
  2. Zelenetz
    Zelenetz
  3. Levine
    Levine
  4. Perales
    Perales
  5. O'Reilly
    O'Reilly
  6. Horwitz
    Horwitz
  7. Kernan
    Kernan
  8. Abdel-Wahab
    Abdel-Wahab
  9. Palomba
    Palomba
  10. Moore
    Moore

Groups

  1. Department of Medicine (3837)
  2. Hematologic Malignancies, Division of (3632)
  3. Center for Hematologic Malignancies (3535)
  4. GSK Faculty (1551)
  5. Adult Leukemia (1287)
  6. Sloan Kettering Institute Faculty (1100)
  7. Bone Marrow Transplant (932)
  8. Lymphoma (898)
  9. Tow Center for Developmental Oncology (TCDO) (861)
  10. Executive Committee, Center for Hematologic Malignancies (843)
Search Within
Formats
  1. Meeting Abstract (3937)
  2. Journal Article (1234)
  3. Review (44)
  4. Research Letter (41)
  5. Editorial (33)
  6. Guidelines (13)
  7. Correspondence (7)
  8. Miscellaneous (3)
Groups
  1. Department of Medicine (3837)
  2. Hematologic Malignancies, Division of (3632)
  3. Center for Hematologic Malignancies (3535)
  4. GSK Faculty (1551)
  5. Adult Leukemia (1287)
  6. Sloan Kettering Institute Faculty (1100)

More Groups

People
  1. Sergio Giralt (336)
  2. Andrew Zelenetz (328)
  3. Ross Levine (311)
  4. Martin Tallman (298)
  5. Miguel-Angel Perales (290)
  6. Richard O'Reilly (281)

More People

Years
  1. 2025 (34)
  2. 2024 (215)
  3. 2023 (478)
  4. 2022 (369)
  5. 2021 (284)
  6. 2020 (261)

More Years

Publications
  1. Blood (4946)
  2. Blood Advances (316)
  3. Hematology-American Society of Hematology Education Program (50)

Results (5312)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • RNA splicing factor mutations drive aberrant canonical and cryptic circular RNA biogenesis in leukemia
    Meeting Abstract

    Fernandez, M.; Jin, M.; Jia, Q.; Wu, Y.; Hart, K.; Bargoma, E.; Pangallo, J.; Bradley, R. K.; Abdel-Wahab, O.; Jia, Z.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Patient-reported outcomes from the MCL cohort of the phase 1, seamless design TRANSCEND NHL 001 study of lisocabtagene maraleucel in patients with R/R B-cell NHL
    Meeting Abstract

    Wang, M. L.; Gordon, L. I.; Hirayama, A. V.; Lunning, M. A.; Shi, L.; Guo, S.; Kostic, A.; Eliason, L.; Kumar, J.; Palomba, M. L.
    Blood (2023)

    Fulltext@MSK | Save
  • A real-world evaluation of risk factors for disease progression in patients with polycythemia vera (PV) enrolled in REVEAL
    Meeting Abstract

    Grunwald, M. R.; Zwicker, J. I.; Gerds, A. T.; Burke, J. M.; Xue, Z.; Crowgey, E. L.; Carl, J.; Feldman, P.; Braunstein, E. M.; Oh, S.
    Blood (2023)

    Fulltext@MSK | Save
  • Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell LyLisocabtagene maraleucel in relapsed/refractory large B-cell lymphoma: Real world analysis from the Cell Therapy Consortiummphoma: Real World Analysis from the Cell Therapy Consortium
    Meeting Abstract

    Riedell, P. A.; Grady, C.; Nastoupil, L. J.; Luna, A.; Ahmed, N.; Maziarz, R. T.; Hu, M.; Brower, J.; Hwang, W. T.; Schuster, S. J.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • What is the optimal treatment modality in molecularly defined secondary AML? A multicenter cohort study
    Meeting Abstract

    Shimony, S.; Bewersdorf, J. P.; Shallis, R. M.; Liu, Y. W.; Schaefer, E. J.; Zeidan, A. M.; Goldberg, A. D.; Stein, E. M.; Marcucci, G.; Chen, E. C.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Bleeding and thrombotic outcomes in adults with cancer-associated splanchnic vein thrombosis and thrombocytopenia
    Meeting Abstract

    Michael, A., Jr.; Turizo, M. J. F.; Dodge, L.; Hsu, C.; Barnum, K.; Zwicker, J. I.; Patell, R.
    Blood (2023)

    Fulltext@MSK | Save
  • Development of a fully immunocompetent adoptive transfer in vivo model of Npm1(cA); Idh2(R140Q); Flt3(ITD) AML
    Meeting Abstract

    Sharpe, C.; Johnson, M.; Fobare, S.; Elgamal, O. A.; Harrington, B. K.; Mustonen, A.; Bryant, K.; Cheney, C.; Lerma, J. R.; Truxall, J.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Real-world outcomes of brexucabtagene autoleucel ( brexu-cel) for relapsed or refractory (R/R) adult B-cell acute lymphoblastic leukemia (B-cell ALL): Evidence from the CIBMTR registry
    Meeting Abstract

    Bezerra, E.; Itani, T.; Wudhikarn, K.; Perales, M. A.; Yang, Y.; Gergis, U.; Aribi, A.; Hill, L. C.; Jain, N.; Leonard, J. T.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Preliminary results of a phase 2a clinical trial to evaluate safety, tolerability and antiviral activity of intravenous brincidofovir (BCV IV) in immunocompromised patients with adenovirus infection
    Meeting Abstract

    Grimley, M.; Maron, G.; Gomez, C. A.; Prasad, V. K.; Dara, J.; Papanicolaou, G. A.; Fukushima, K.; Wynn, R. F.; Boeckh, M.
    Blood (2023)

    Fulltext@MSK | Save
  • Low dose total body irradiation improves CD19 CAR-T expansion, persistence, and trafficking, leading to enhanced efficacy in large B-cell lymphoma
    Meeting Abstract

    Alhomoud, M.; Foley, M.; Sugita, M.; Yamazaki, T.; Martinez, L.; Yamshon, S.; Gomez-Arteaga, A.; Pagnini, P.; Shore, T. B.; Boyer, O.; more...
    Blood (2023)

    Fulltext@MSK | Save